ALEMBIC
|
|
BOM : 506235     NSE : ALEMBICLTD     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Apr 25,2024 |
Price(EOD): ₹ 94.82
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 2,434.98 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ALEMBIC | 2.5% | 16.4% | 58.3% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
CIPLA | 4.5% | -3.1% | 52.8% |
DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
MANKIND PHARMA | 2.7% | 12.4% | NA |
TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
LUPIN | 3.1% | -1.1% | 127.4% |
FUNDAMENTAL ANALYSIS OF ALEMBIC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ALEMBIC
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
31.92
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 76.29 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] 1.17
P/B Calculated based on Book Value of Rs 2,078.03 Cr
[Latest Year - Mar2023 - Consolidated Results ] 16.73
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 145.56 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
400% 42% 42% |
SHARE PRICE MOMENTUM OF ALEMBIC
ALEMBIC vs SENSEX
DEBT OF ALEMBIC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0 0 0 - |
0 0 0 - |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ALEMBIC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ALEMBIC
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
21.81% 15.07% -80.58% -80.82% |
28.45% 11.88% -1.81% -8.32% |
QtrlyTrend |
0 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
ALEMBIC related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.2% | 12.8% | 65.7% |
S&P BSE MIDSMALLCAP | 2.4% | 10.7% | 64.9% |
S&P BSE CONSUMER DISC. | 1.7% | 8.7% | 60.4% |
S&P BSE ALLCAP | 1.6% | 6% | 40.6% |
You may also like the below Video Courses
FAQ about ALEMBIC
Is ALEMBIC good for long term investment?
As on Apr 25,2024, the Fundamentals of ALEMBIC look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of ALEMBIC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ALEMBIC UnderValued or OverValued?
As on Apr 25,2024, ALEMBIC is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ALEMBIC ?
As on Apr 25,2024, the Intrinsic Value of ALEMBIC is Rs. 66.70 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 18.96
Fair Value [Median EV / Sales Model] : Rs. 66.72
Fair Value [Median Price / Sales Model] : Rs. 66.70
Estimated Median Fair Value of ALEMBIC : Rs. 66.70
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.